1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Pathological Complete Response: new trials by email Literature Review of Pathological Complete Response trials Research Report on Pathological Complete Response
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma Tislelizumab, Paclitaxel, Cisplatin - ESCC, Total Neoadjuvant Treatment | Phase 2 | Recruiting | National Taiwan University Hospital | 50 | 2025-07-23 | 2026-01-27 |
Chemoradiotherapy (1) · Cisplatin (1) · Paclitaxel (1) · tislelizumab (1)
National Taiwan University Hospital (1)
Taiwan (1)